|
02 Mar 2022 |
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
|
|
24 Feb 2022 |
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
|
|
23 Feb 2022 |
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
|
|
23 Feb 2022 |
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
|
|
21 Feb 2022 |
GSK provides update on phase III RSV maternal vaccine candidate programme
|
|
16 Feb 2022 |
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
|
|
16 Feb 2022 |
PharmaJet Partner Technovalia Announces Interim Results of Needle-free COVID-19 Vaccine Trial
|
|
16 Feb 2022 |
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
|
|
12 Feb 2022 |
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
|
|
08 Feb 2022 |
Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
|
|
08 Feb 2022 |
Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
|
|
04 Feb 2022 |
Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
|
|
04 Feb 2022 |
AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
|
|
03 Feb 2022 |
EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea
|
|
02 Feb 2022 |
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
|
|
01 Feb 2022 |
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
|
|
01 Feb 2022 |
Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
|
|
01 Feb 2022 |
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
|
|
28 Jan 2022 |
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
|
|
27 Jan 2022 |
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
|
|
25 Jan 2022 |
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
|
|
25 Jan 2022 |
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
|
|
13 Jan 2022 |
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
|
|
13 Jan 2022 |
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
|
|
07 Jan 2022 |
Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
|
